Literature DB >> 31493307

Impact of regular Breast Self-Examination on breast cancer size, stage, and mortality in Thailand.

Vallop Thaineua1, Tamnit Ansusinha1, Nanta Auamkul2, Surasak Taneepanichskul2, Chonlatit Urairoekkun3, Jaruwun Jongvanich3, Chalermdej Kannawat1, Patrinee Traisathit4, Imjai Chitapanarux5.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31493307      PMCID: PMC7216887          DOI: 10.1111/tbj.13611

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


× No keyword cloud information.
The incidence of breast cancer in Thailand has increased during the past decade. Besides, most of the patient present with the locally advanced stage.1 Mammography has not reached all women in Thailand. Breast self‐examination (BSE) is simple and feasible for breast cancer screening among developing countries comparing to mammography and clinical breast examination (CBE).2 We evaluate a cohort study of 1 906 697 women without a history of breast cancer aged 30‐70 years who participated in a breast cancer awareness program in Thailand. We excluded women with known breast cancer or in process of investigation. BSE program in this study was shown in Figure 1. The village health volunteers (VHV) helped reminding the cohorts to perform BSE regularly through the use of BSE record booklet. The innovative BSE record booklet contained the instruction to help cohort to perform BSE precisely and record monthly in the booklet which was verified by the VHV and confirmed by health personnel. The participants had been followed up from October 2012 to September 2017. The participants who reached the regularity (at least once in every 2 months) of BSE within 12 months before diagnosis were defined as regular BSE. When abnormalities presented, the participants were referred for screening by CBE then confirmed by imaging and pathology. The data of BSE and Breast Cancer Individual (BCI) Record Form were collected and analyzed. There were 2,956 women diagnosed with breast cancer in this study (Figure 2). Breast cancer size and stage were diagnosed according to the AJCC 7th staging system. We categorized tumor size into small (≤2 cm) and large (>2 cm) and stage into early (0–II) and late (III‐IV). Death due to breast cancer was also recorded.
Figure 1

The process of data collection and analysis

Figure 2

Flow chart of breast cancer diagnosis

The process of data collection and analysis Flow chart of breast cancer diagnosis Of 1 906 697 women who participated in this study, 61% were aged < 50 years. 72% of participants performed BSE regularly. During 5 years of follow‐up, 2956 participants were diagnosed with breast cancer. The average incidence rate per year was 31 (range 27.5‐33.5) per 100 000 women aged between 30 and70 years old (Table 1). 97.9% of them found a breast lump themselves and were sent for confirmation by imaging and histopathology. The other presenting symptoms were breast pain (12.8%) and unequal breast size (7.9%). Some of participants (1.2%) did not have any signs or symptoms. Data on breast cancer size were available for 2,031 patients (68.7% of all patients with breast cancer). The risk of a large tumor size in nonregular BSE patients was 1.348‐fold higher than regular BSE patients. Data on breast cancer stage were available for 2659 patients (90.0% of all patients with breast cancer). Most of the patients were diagnosed with stage II, (47.9%) and 31.5% were diagnosed with stage III‐IV. The risk of late‐stage breast cancer in nonregular BSE patients was 1.319‐fold higher than in regular BSE. Of 2956 patients, 176 (5.9%) died during 5 years of follow‐up. The survival rate of regular BSE patients was significantly higher than nonregular BSE patients (95.7% vs 92.6%, P‐value < .001). Nonregular BSE patients had a 1.702‐fold higher incidence of mortality than regular BSE patients (OR = 1.702; 95%CI = 1.235‐2.347; P‐value < .05) (Table 2).
Table 1

Participants characteristics

 n (%)
Participants1 906 697 (100)
BSE data1 754 310 (92.0)
Regular BSE1 262 241 (72.0)
Breast cancer patients2956 (0.2)
2013631 (21.3)
2014582 (19.7)
2015579 (19.6)
2016639 (21.6)
2017525 (17.8)
Incidence rate/year (per 100 000)31.0
Size ≤ 2 cm843 (41.5)
Stage 0–II1820 (68.5)
Breast cancer mortality176 (5.9)
Table 2

Breast self‐examination and breast cancer size, stage, and mortality

Breast self‐examinationSize (N = 1938) P‐valueStage (N = 2557) P‐valueMortality (N = 2804) P‐value
≤2 cm>2 cmOdds ratioEarlyLateOdds ratioAliveDeadOdds ratio
n (%)n (%)(95%CI)n (%)n (%)(95%CI)n (%)n (%)(95%CI)
Regular602 (43.1)794 (56.9)1.348 (1.090‐1.667)<.011300 (70.3)550 (29.7)1.319 (1.094‐1.591)<.011901 (95.0)100 (5.0)1.702 (1.235‐2.347)<.05
Nonregular202 (37.3)340 (62.7)458 (64.8)249 (35.2)737 (91.8)66 (8.2)
Participants characteristics Breast self‐examination and breast cancer size, stage, and mortality This study has higher rate of regular BSE than others 3, 4, 5 because of the strong collaboration from VHV and BSE booklet. Most of women who developed breast cancer from BCI record found breast lump themselves. Our findings are consistent with the others 6, 7; we reported a significantly higher proportion of smaller tumor size, earlier stage, and better survival rate in regular BSE practiced women rather than nonpracticing women. In the developed countries, they recommend women aged 50‐74 years should have mammography screening once every 2‐3 years,8, 9 which indicates that mammography could not cover all age groups. Despite the efficacy of BSE to decrease breast cancer mortality is largely unproven. This large Thai cohort study indicates that regular BSE recorded in the BSE record booklet and monitored by VHV is effective for the early detection of breast cancer.
  9 in total

1.  Awareness and practice of breast self examination among malaysian women with breast cancer.

Authors:  Siew Yim Loh; S L Chew
Journal:  Asian Pac J Cancer Prev       Date:  2011

2.  Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.

Authors:  Albert L Siu
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

3.  Breast Cancer Risks and Effectiveness of BSE Training among Women Living in a District of İstanbul.

Authors:  Kamer Gür; Hasibe Kadıoğlu; Ayşe Sezer
Journal:  J Breast Health       Date:  2014-07-01

4.  Awareness and practice of breast self-examination among Korean women: results from a nationwide survey.

Authors:  Bit-Na Yoo; Kui Son Choi; Kyu-Won Jung; Jae Kwan Jun
Journal:  Asian Pac J Cancer Prev       Date:  2012

5.  Evaluation of breast self-examination (BSE) application in first and second degree relatives of patients with breast cancer.

Authors:  Hatice Bebis; Serife Zehra Altunkurek; Cengizhan Acikel; Ilker Akar; Serife Zehra Altunkurek
Journal:  Asian Pac J Cancer Prev       Date:  2013

6.  Breast self examination and survival from breast cancer.

Authors:  M Le Geyte; D Mant; M P Vessey; L Jones; P Yudkin
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

7.  Assessing Breast Cancer Awareness in Thai Women: Validation of the Breast Cancer Awareness Scale (B-CAS)

Authors:  Nitchamon Rakkapao; Supannee Promthet; Malcolm Anthony Moore; Solikhah Solikhah; Cameron Hurst
Journal:  Asian Pac J Cancer Prev       Date:  2017-04-01

8.  Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial.

Authors:  Anthony B Miller; Claus Wall; Cornelia J Baines; Ping Sun; Teresa To; Steven A Narod
Journal:  BMJ       Date:  2014-02-11

9.  The effect of breast self-examination on early detection and survival.

Authors:  T Kuroishi; S Tominaga; J Ota; T Horino; T Taguchi; T Ishida; T Yokoe; M Izuo; M Ogita; S Itoh
Journal:  Jpn J Cancer Res       Date:  1992-04
  9 in total
  1 in total

1.  Breast self-examination practice and its determinants among women in Ethiopia: A systematic review and meta-analysis.

Authors:  Yordanos Gizachew Yeshitila; Getachew Mullu Kassa; Selamawit Gebeyehu; Peter Memiah; Melaku Desta
Journal:  PLoS One       Date:  2021-01-14       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.